Heart Closure Devices Market is anticipated to be worth US$ 10.88 billion by 2033 | FMI Analyst

The global Heart Closure Devices Market is expected to be valued at US$ 2.71 Billion in 2023. The overall demand for heart closure devices is anticipated to increase at a CAGR of 14.9% between 2023 and 2033, reaching a total of roughly US$ 10.88 Billion by 2033 due to the rise in demand for highly effective procedures among people and the rise in research and development spending for developing innovative and technologically advanced products.

Factors such as an increase in incidence of congenital heart defects, technological advancements in heart closure devices, rise in adoption of MRI procedures, and upsurge in geriatric population are expected to augment the growth of the global heart closure devices market over the analysis period.

On the other hand, high cost of production and stringent regulations associated with these devices limit the market growth. Whereas, an increase in number of heart strokes and development of innovative products by key players are expected to provide lucrative avenues for market expansion in the forthcoming years.

Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15937

Furthermore, the utilization of 3D imaging and anatomical models in the manufacturing and planning processes of heart closure devices is gaining prominence in the market. This is expected to change the supply landscape of the industry, attributed to characteristics such as personalization, adaptability, and flexibility provided by using 3D imaging technology.

This in turn decreases the overall prostheses employed per patient along with the procedure time, which makes it a viable option in the production and planning process. Similarly, continuous new product launches as well as approvals along with rapid expansion of healthcare industry across emerging economies will bode well for the market growth in the near future.

Cardiac Occlusion Devices are medical devices used to close a hole or defect in the wall between the two upper chambers of the heart, known as the atria. These devices are used to treat a condition called atrial septal defect (ASD) or patent foramen ovale (PFO).

Key Takeaways from the Market Study

• Global heart closure devices market was valued at US$ 2.36 Billion by 2022-end
• From 2018 to 2022, the market demand expanded at a CAGR of 6.6%
• By Closure Type, the left atrial appendage closure segment of the market constitutes the bulk of the market with a market share of 49%
• By End-User, the Hospitals segment dominates the market with a share of 47%
• From 2023 to 2033, Heart Closure Devices sales are expected to flourish at a CAGR of 14.9%.
• By 2033, the market value of Heart Closure Devices is expected to reach US$ 10.88 Billion

“The rise in patient pool globally, and growing awareness about heart diseases positively are the major factors driving the growth of the Heart Closure Devices Market during the forecast period,” remarks an FMI analyst.

Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15937

Competitive Landscape

Players in the global Heart Closure Devices Market focus on expanding their global reach through various strategies, such as; partnerships, collaborations, and partnerships. The players are also making a significant investment in R&D to add innovations to their products which would help them in strengthening their position in the global market. Some of the recent developments among the key players are:

• In July 2021, Angel Medical Systems, Inc. announced the first commercial implantation of their flagship product, “The Guardian” device in the U.S. region. This was the first procedure followed by their recent FDA approval.
• In April 2021, Phoenix Cardiac Devices, Inc. announced that they received a CE Mark for their product, BACE (Basal Annuloplasty of the Cardio externally) device. This approval helps in the commercialization of BACE in the European Union.
• In March 2021, the U.S. FDA announced the approval of the world’s first non-surgical heart valve treatment for pediatric and adult patients suffering from a native or surgically repaired right Ventricular outflow tract (RVOT). The device was specifically developed to treat patients with severe pulmonary heart regurgitation.

Key Companies Profiled:

• Abbott
• W. L. Gore & Associates, Inc.
• Boston Scientific Corp.
• Occlutech
• Heartstitch
• SMT
• Cardia, Inc.
• Lifetech Scientific Corp.
• Lepu Medical Technology
• AtriCure Inc.

For more Report Customization, connect with us @ https://www.futuremarketinsights.com/customization-available/rep-gb-15937

Key Segments Covered in the Heart Closure Devices Industry Analysis

Heart Closure Devices Market by Closure Type:

• Congenital Heart Defect Closure
  • Atrial Septal Defect (ASD)
  • Patent Ductus Arteriosus (PDA)
  • Ventricular Septal Defect (VSD)
• Patent Foramen Ovale (PFO) Closure
• Left Atrial Appendage (LAA) Closure

Heart Closure Devices Market by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs